title: Acute pharmacological modulation of mGluR8 reduces measures of anxiety.
abstract: Metabotropic glutamate receptors (mGluRs), which are coupled to second messenger pathways via G proteins, modulate glutamatergic and GABAergic neurotransmission. Because of their role in modulating neurotransmission, mGluRs are attractive therapeutic targets for anxiety disorders. Previously we showed that mGluR8(-/-) male mice showed higher measures of anxiety in the open field and elevated plus maze than age-matched wild-type mice. In this study, we assessed the potential effects of acute pharmacological modulation of mGluR8 on measures of avoidable and unavoidable anxiety. In addition to wild-type mice, we also tested apolipoprotein E-deficient (Apoe(-/-)) mice, as these mice show increased levels of anxiety-like behaviors and therefore might show an altered sensitivity to mGluR8 stimulation. mGluR8 stimulation with the specific agonist DCPG, or modulation with AZ12216052, a new, positive allosteric modulator of mGluR8 reduced measures of anxiety in both wild-type mice. The effects of mGluR8 positive allosteric modulators, which only affect neurotransmission in the presence of extracellular glutamate, seem particularly promising for patients with anxiety disorders showing benzodiazepine insensitivity.
authors.affiliation: Department of Physiology and Pharmacology, Oregon Health & Science University, Portland, OR, USA.
authors.forename: Robert M
authors.initials: RM
authors.lastname: Duvoisin
authors.forename: Tim
authors.initials: T
authors.lastname: Pfankuch
authors.forename: Julie M
authors.initials: JM
authors.lastname: Wilson
authors.forename: Julie
authors.initials: J
authors.lastname: Grabell
authors.forename: Vijay
authors.initials: V
authors.lastname: Chhajlani
authors.forename: Dean G
authors.initials: DG
authors.lastname: Brown
authors.forename: Edwin
authors.initials: E
authors.lastname: Johnson
authors.forename: Jacob
authors.initials: J
authors.lastname: Raber
mesh_terms: D000083:Acetanilides / Q000494:pharmacology; D000818:Animals; D001007:Anxiety / Q000188:drug therapy / Q000378:metabolism*; D001057:Apolipoproteins E / Q000235:genetics / Q000378:metabolism; D001307:Auditory Perception / Q000187:drug effects / Q000502:physiology; D001565:Benzoates / Q000494:pharmacology; D002491:Central Nervous System Agents / Q000494:pharmacology; D005998:Glycine / Q000031:analogs & derivatives / Q000494:pharmacology; D008297:Male; D018782:Maze Learning / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009483:Neuropsychological Tests; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists / Q000378:metabolism*; D013216:Reflex, Startle / Q000187:drug effects / Q000502:physiology; D013864:Thioglycolates / Q000494:pharmacology; D013997:Time Factors
chemical_list: C110733:3,4-dicarboxyphenylglycine; C552361:AZ 12216052; D000083:Acetanilides; D001057:Apolipoproteins E; D001565:Benzoates; D002491:Central Nervous System Agents; D018094:Receptors, Metabotropic Glutamate; D013864:Thioglycolates; C111435:metabotropic glutamate receptor 8; D005998:Glycine
references.citation: J Pharmacol Exp Ther. 1998 Feb;284(2):651-60
references.pmid: 9454811
references.citation: Eur Arch Psychiatry Clin Neurosci. 1994;244(1):49-51
references.pmid: 7918702
references.citation: Nat Rev Drug Discov. 2005 Feb;4(2):131-44
references.pmid: 15665858
references.citation: J Physiol. 1996 Oct 1;496 ( Pt 1):175-84
references.pmid: 8910206
references.citation: Pharmacol Biochem Behav. 2002 Sep;73(2):367-74
references.pmid: 12117591
references.citation: Neuropharmacology. 2002 Aug;43(2):251-9
references.pmid: 12213279
references.citation: Behav Brain Res. 2010 May 1;209(1):21-6
references.pmid: 20080129
references.citation: Eur J Neurosci. 2005 Jul;22(2):425-36
references.pmid: 16045496
references.citation: Eur J Pain. 2010 Feb;14(2):113-9
references.pmid: 19423371
references.citation: Pharmacol Biochem Behav. 2002 Sep;73(2):327-32
references.pmid: 12117586
references.citation: J Neurosci. 1995 Apr;15(4):3075-83
references.pmid: 7722646
references.citation: J Med Chem. 1997 Feb 14;40(4):528-37
references.pmid: 9046344
references.citation: Nature. 1997 Jul 24;388(6640):377-80
references.pmid: 9237754
references.citation: Neurobiol Aging. 2005 May;26(5):637-43
references.pmid: 15708438
references.citation: Science. 1993 Jul 2;261(5117):104-6
references.pmid: 8391168
references.citation: Neuropsychopharmacology. 2004 Mar;29(3):441-9
references.pmid: 14628000
references.citation: Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3093-8
references.pmid: 15705714
references.citation: Neuroscience. 2003;121(1):167-78
references.pmid: 12946709
references.citation: Neuroscience. 2006;137(2):413-23
references.pmid: 16330151
references.citation: Mol Pharmacol. 1997 Jan;51(1):119-25
references.pmid: 9016353
references.citation: Genes Brain Behav. 2010 Feb;9(1):33-44
references.pmid: 19740090
references.citation: Brain Res. 2008 Apr 14;1204:53-8
references.pmid: 18342296
references.citation: Annu Rev Pharmacol Toxicol. 1997;37:205-37
references.pmid: 9131252
references.citation: Neuron. 1993 Nov;11(5):837-44
references.pmid: 8240807
references.citation: J Neurochem. 2000 Sep;75(3):889-907
references.pmid: 10936169
references.citation: J Pharmacol Exp Ther. 2008 Nov;327(2):584-91
references.pmid: 18664590
references.citation: Psychoneuroendocrinology. 1997 Jan;22(1):25-38
references.pmid: 9141149
references.citation: Neuropharmacology. 1995 Feb;34(2):181-90
references.pmid: 7617144
references.citation: Pharmacol Rep. 2005 Nov-Dec;57(6):856-60
references.pmid: 16382208
references.citation: Nat Med. 2003 Jan;9(1):76-81
references.pmid: 12461523
references.citation: Br J Pharmacol. 1997 May;121(2):199-204
references.pmid: 9154328
references.citation: Neuropharmacology. 2003 Sep;45(4):473-83
references.pmid: 12907308
references.citation: Agents Actions. 1984 Apr;14(3-4):534-7
references.pmid: 6328954
references.citation: Psychopharmacology (Berl). 2003 Aug;168(4):446-54
references.pmid: 12709777
references.citation: Neuropharmacology. 1995 Jan;34(1):1-26
references.pmid: 7623957
references.citation: Neuropharmacology. 2001 Mar;40(3):311-8
references.pmid: 11166323
references.citation: J Neurosci. 2000 Mar 1;20(5):2064-71
references.pmid: 10684907
references.citation: Psychopharmacology (Berl). 1986;88(2):147-52
references.pmid: 3081925
references.citation: Psychopharmacology (Berl). 1993;110(3):342-6
references.pmid: 7831429
references.citation: Neuropsychopharmacology. 1989 Dec;2(4):285-92
references.pmid: 2610824
references.citation: Am J Psychiatry. 1996 Nov;153(11):1444-9
references.pmid: 8890678
references.citation: J Psychiatr Res. 1995 Sep-Oct;29(5):427-34
references.pmid: 8748067
references.citation: Neuropharmacology. 2008 Sep;55(4):537-45
references.pmid: 18533199
references.citation: J Neurosci. 1992 Jun;12(6):2303-12
references.pmid: 1351540
references.citation: Prog Neurobiol. 2001 Apr;63(6):637-72
references.pmid: 11164999
references.citation: Neuropharmacology. 2006 Feb;50(2):154-64
references.pmid: 16188284
references.citation: Pain. 2001 Sep;93(3):239-245
references.pmid: 11514083